-
Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish'
Monday, October 10, 2022 - 10:39am | 237Read More...Merck & Co. Inc. (NYSE: MRK) seems well positioned to surpass 2023 consensus estimates, driven by margin potential, according to Guggenheim. The Analyst: Seamus Fernandez upgraded the rating for Merck from Neutral to Buy, while establishing a price target of $104. The Thesis: The company’...
-
Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk
Monday, October 19, 2020 - 3:24pm | 406Read More...An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-oncology drug Opdivo. The Bristol-Myers Squibb Analyst: Analyst Seamus Fernandez upgraded Bristol-Myers Squibb...
-
Intense Competition Pressures Eli Lilly, Leerink Downgrades
Wednesday, July 26, 2017 - 10:58am | 442Read More...Despite a strong quarter, analysts see a difficult road ahead for Eli Lilly And Co (NYSE: LLY). “Even though Eli Lilly's launch execution has been outstanding," Leerink Managing Director Seamus Fernandez said, "the ways for LLY investors to win in our view appear limited when...
-
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Monday, March 20, 2017 - 9:17am | 1119Read More...In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...
-
The Best BioPharma Plays Amid Uncertainty From Trump Comments
Thursday, January 12, 2017 - 2:58pm | 336Read More...Pharma sector was hit following the comments made by President-elect Donald Trump who alluded to potential tightening of industry regulation. At his first press conference since being elected, Trump said the pharmaceutical industry is “getting away with murder” in terms of product...
-
Tesaro Shares Lower On Receipt Of FDA Complete Response Letter
Thursday, January 12, 2017 - 11:33am | 340Read More...On Wednesday, TESARO Inc (NASDAQ: TSRO) announced it had received a complete response letter from the FDA for its candidate, Varubi, in chemotherapy-induced nausea and vomiting. Leerink’s Seamus Fernandez maintains an Outperform rating on the company. Temporary Setback According to Tesaro...
-
Why The Amgen/Regeneron Patent Saga Is Far From Over
Monday, January 9, 2017 - 1:27pm | 422Read More...Despite the District Court’s ruling in favor of Amgen, Inc. (NASDAQ: AMGN) over cholesterol drug Praluent, Leerink believes the patent dispute with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) is far from over given the possibility of appeal by these firms and...
-
A Pfizer Split Is 'Clearly' On The Table
Thursday, May 5, 2016 - 10:59am | 245Read More...Leerink’s Seamus Fernandez believes the decision to split Pfizer Inc. (NYSE: PFE) into Established and Innovative Businesses was likely to be announced by end-2016, with the split being completed by end-2017. The analyst maintained a Market Perform rating on the company, while raising the...
-
This Data Signals The End For Merck's Anacetrapib
Monday, April 4, 2016 - 11:33am | 281Read More...The ACCELERATE study data for Evacetrapib, which is a selective inhibitor of cholesteryl ester transfer protein [CETP] of Eli Lilly and Co (NYSE: LLY), was presented at the 2016 American College of Cardiology Conference. Leerink’s Seamus Fernandez mentioned that the data “clearly...
-
Novartis Shares Downgraded, Leerink Says 'Consensus Still Way Too High'
Wednesday, March 23, 2016 - 9:32am | 273Read More...Leerink’s Seamus Fernandez downgraded the rating for Novartis AG (ADR) (NYSE: NVS) from Outperform to Market Perform, while reducing the price target from $98 to $85. The analyst said that the consensus sales expectations for Entresto seemed unrealistic. Heart Failure [HF] guideline...
-
Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns
Monday, December 28, 2015 - 10:59am | 259Read More...Eli Lilly and Co (NYSE: LLY) shares have appreciated 24.44 percent year-to-date, from trading close to the 52-week low on December 31, 2014, at $68.99. Leerink’s Seamus Fernandez has maintained an Outperform rating on the company, while raising the price target from $93 to $95....
-
FDA Approves Allergan's Ozurdex, Rejects Levadex
Monday, June 30, 2014 - 12:08pm | 134Read More...The FDA on Monday approved Allergan's (NYSE: AGN) diabetic macular edema (DME) drug Ozurdex. Allergan's drug Levadex, a migraine treatment, was rejected by the FDA. Wells Fargo analyst Larry Biegelsen is projecting a positive outcome for Allergan with its latest stage in development....
-
UPDATE: Leerink Swann Downgrades Sanofi Based on Low Visibility
Friday, October 18, 2013 - 12:14pm | 183Read More...In a report published Friday, Leerink Swann analyst Seamus Fernandez downgraded Sanofi (NYSE: SNY) from Outperform to Market Perform and lowered the PT from €83 ($113.7142) to €80 ($109.6191) based on low visibility in the company's recovery. Fernandez noted that this valuation does not include...
-
Fast Money 360: Leerink Swann Is A Buyer Of Merck (MRK)
Wednesday, July 28, 2010 - 6:39pm | 187Read More...Seamus Fernandez of Leerink Swann said on CNBC's Fast Money 360 that he is a buyer of Merck (NYSE: MRK) ahead of earnings. He added that Merck (MRK) is his top pick in the group, and he doesn't expect any surprises in the quarter. Carter Worth of Oppenheimer thinks that whatever happens on earnings...
